Epidemiology of invasive fungal infection

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  Caston Osorio J J ^a   Rivero, A ^a   Torre Cisneros, J ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Candida; Epidemiology; Filamentous fungi; Invasive fungal infection; Risk factor

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CALCINEURIN INHIBITOR; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDEMIA; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DISEASE TRANSMISSION; FUNGEMIA; FUSARIUM; GEOTRICHUM CAPITATUM; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MUCORALES; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; PHAEOHYPHOMYCOSIS; PRIORITY JOURNAL; RHODOTORULA; RISK FACTOR; SCEDOSPORIUM APIOSPERMUM; TRICHOSPORON; WATER SUPPLY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; MUCORMYCOSIS; RISK FACTORS;

EID: 55649109052     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70009-8     Document Type: Article

References (92)

1. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37 (2003) 634-643
2. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
3. Mc Neil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33 (2001) 641-647
4. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., and Gaynes R.P. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35 (2002) 627-630
5. Beck-Sague C.M., and Jarvis W. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 167 (1993) 1247-1251
6. Voss A., Kluytmans J.A., Koeleman L., Spanjaard L., Vandenbroucke-Grauls C.M., Verbrugh H.A., et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 15 (2006) 909-912
7. Marchetti O.J., Bille U., Fluckiger P., Eggiman C., Ruef F., Garbino J., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 38 (2004) 311-320
8. Asmundsdottir L.R., Erlendsdottir H., and Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40 (2002) 3489-3492
9. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Jensen I.M., Knudsen J.D., Lundgren B., et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43 (2005) 4434-4440
10. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43 (2005) 1829-1835
11. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., et al. Incidence of bloodstream infections due to Candida species and in vitro surveillance of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42 (2004) 1519-1527
12. Kung H.C., Wang J.L., Chang S.C., Wang J.T., Sun H.Y., Hsueh P.R., et al. Community-onset candidemia at a university hospital, 1995-2005. J Microbiol Immunol Infect 40 (2007) 355-363
13. Marr K.A., Seidel K., Slavin M.A., Borden R.A., Schoch H.G., Flowers M.E., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96 (2000) 205-261
14. Singh N., Wagener M.M., Marino J.R., and Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 73 (2002) 63-67
15. Husain S., Wagener M.M., and Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 7 (2001) 375-381
16. Vilchez R.A., Fung J., and Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2 (2002) 575-580
17. Singh N., Alexander B.D., Lortholary O., Dromer F., Gupta K.L., John G.T., et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 46 (2008) 12-18
18. Singh N., Alexander B.D., Lortholary O., Dromer F., Gupta K.L., John G.T., et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 195 (2007) 756-764
19. Sugita T., Nishikawa A., Shinoda T., and Kume H. Taxonomic position of deep-seated, mucosa-associated, and superficial isolates of Trichosporon cutaneum from trichosporonosis patients. J Clin Microbiol 33 (1995) 1368-1370
20. Pfaller M.A., and Diekema D.J. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42 (2004) 4419-4431
21. Walsh T.J., Groll A., Hiemenz J., Fleming R., Roilides E., and Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10 Suppl 1 (2004) 48-66
22. Rodrigues Gda S., de Faria R.R., Guazzelli L.S., Oliveira F.M., and Severo L.C. Nosocomial infection due to Trichosporon asahii: clinical revision of 22 cases [in Spanish]. Rev Iberoam Micol 23 (2006) 85-89
23. Walsh T.J., Melcher G., and Rinaldi M. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B. J Clin Microbiol 28 (1990) 1616-1622
24. Paphitou N.I., Ostrosky-Zeichner L., Paetznick V.L., Rodriguez J.R., Chen E., and Rex J.H. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 46 (2002) 1144-1146
25. Tawara S., Ikeda F., Maki K., Morixhita Y., Otomo K., Teratani T., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44 (2000) 57-62
26. Uzun O., Kocagoz S., Centikaya Y., Arikan S., and Unal S. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 41 (1997) 1156-1157
27. Salkin I.F., Gordon M.A., Samsonoff W.A., and Rieder C.L. Blastoschizomyces capitatus, a new combination. Mycotaxon 22 (1985) 375-380
28. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Lebeau B., et al. Candidemia in cancer patients. A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28 (1999) 1071-1079
29. D'Antonio D., Piccolomini R., Fioritoni G., Iacone B., Violante M.A., Capuani A.P., et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 34 (1996) 753-755
30. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36 (1998) 198-202
31. Venditti M., Posteraro B., Morace G., and Martino P. In vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus. J Chemother 3 (1991) 13-15
32. Gadea I., Cuenca-Estrella M., Prieto E., Diaz-Guerra M., Garcia-Cia I., Mellado E., et al. Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital. J Clin Microbiol 42 (2004) 1832-1836
33. Lunardi L.W., Aquino V.R., Zimerman R.A., and Goldani L.Z. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 43 (2006) 60-63
34. Eisenberg E.S., Alpert B.E., Weiss A., Mittman N., and Soeiro R. Rhodotorula rubra peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Am J Med 75 (1983) 349-352
35. Hsueh P.R., Teng L.J., Ho S.W., and Luh K.T. Catheter-related sepsis due to Rhodotorula glutinis. J Clin Microbiol 41 (2003) 857-859
36. Lanzafame M., DeChecchi G., Parinello A., Trevenzoli M., and Cattelan M. Rhodotorula glutinis-related meningitis. J Clin Microbiol 39 (2001) 410
37. Guerra R., Cavallini G.M., Longanesi L., Casolani C., Bertoli G., Rivasi F., et al. Rhodotorula glutinis keratitis. Int Ophtalmol 16 (1992) 187-190
38. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Meis J.F., Gould I.M., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45 (2007) 1735-1745
39. Zaas A.K., Boyce M., Schell W., Lodge A., Miller J.L., and Perfect J.R. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 41 (2003) 5233-5235
40. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
41. Gómez-López A., Mellado E., Rodríguez-Tudela J.L., and Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp and literature review. J Antimicrob Chemother 55 (2005) 312-316
42. a edición. (2006), Editorial Panamericana, Madrid 653-663
43. Revankar S.G., Sutton D.A., and Rinaldi M.G. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 38 (2004) 206-216
44. Teixeira A.H., Trabaos A.P., Moretti-Branchini M.L., Auki F.H., Vigorito A.L., et al. Phaeohyphomycosis caused by Chaetomium globosum in an allogeneic bone marrow transplant recipient. Mycopathologia 156 (2003) 309-312
45. Singh N., Chang F.Y., Gayowski T., and Marino I.R. Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis 24 (1997) 369-374
46. Benito N., Moreno A., Puig J., and Rimoli A. Alternariosis after liver transplantation. Transplantation 72 (2001) 1840-1843
47. Yehia M., Thomas M., Dilmore H., Van der Merwe W., and Dittner I. Subcutaneous black fungus (phaeohyphomycosis) infection in renal transplant recipients: three cases. Transplantation 77 (2004) 140-142
48. Silveria F., and Nucci M. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opin Infect Dis 14 (2001) 679-684
49. McGinnis M.R., and Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol 36 (1998) 2353-2355
50. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-09991 (L743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeast. J Clin Microbiol 36 (1998) 2950-2956
51. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K., et al. Trends in post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
52. Chandrasekar P.H., Curtright J.L., and Manavathu E.K. Aspergillus rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Mycology 41 (2001) 211-214
53. Van Burik J.H., Leisenring W., Myerson D., Hackman R.C., Shulman H.M., Sale G.E., et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. Medicine (Baltimore) 77 (1998) 246-254
54. Kontoyiannis D.P. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis?. Clin Infect Dis 34 (2002) 1281-1283
55. Upton A., Kirby K.A., Carpenter P., Boeckh M., and Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44 (2007) 531-540
56. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33 (2001) 1692-1696
57. Garnacho-Montero J., Amaya-Villar R., Ortiz-Leyba C., Leon C., Alvarez-Lerma F., Nolla-Salas J., et al. Isolation of Aspergillus spp from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 9 (2005) R191-R199
58. Meersseman W., Lagrou K., Maertens J., and Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45 (2007) 205-216
59. Baddley J.W., Stroud T.P., Salzman D., and Pappas P.G. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 32 (2001) 1319-1324
60. Iwen P.C., Rupp M.E., Langnas A.N., Reed E.C., and Hinrichs S.H. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 26 (1998) 1092-1097
61. Steinbach W.J., Benjamín Jr. D.K., Kontoyiannis D.P., Perfect J.R., Lutsar I., Marr K.A., et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39 (2004) 192-198
62. Castón J.J., Linares M.J., Gallego C., Rivero A., Font P., Solís F., et al. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi. Chest 131 (2007) 230-236
63. Lass-Fl̈orl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 131 (2005) 201-207
64. Singh N., Limaye A.P., Forrest G., Safdar N., Muñoz P., Pursell K., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 44 (2006) 445-449
65. Junghanss C., and Marr K.A. Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?. Curr Opin Infect Dis 15 (2002) 347-353
66. Upton A., Kirby K.A., Carpenter P., Boeckh M., and Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44 (2007) 531-540
67. Labbé A.C., Su S.H., Laverdière M., Pépin J., Patiño C., and Cohen S. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 13 (2007) 1192-1200
68. Einsele H.H., Hebart H., Kauffmann-Schneider C., Sinzger C., Jahn G., Bader P., et al. Risk factors for treatment failures in patients receiving PCR-based pre-emptive therapy for CMV infection. Bone Marrow Transplant 25 (2000) 757-763
69. Singh N., Avery R.K., Muñoz P., Pruett T.L., Alexander B., Jacobs R., et al. Trends in risk-profiles and mortality due to invasive aspergillosis in liver transplant recipients. Clin Infect Dis 36 (2003) 45-52
70. Gavaldá J., Len O., San Juan R., Aguado J.M., Fortun J., Lumbreras C., et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 41 (2005) 52-59
71. Sampathkumar P., and Paya C.V. Fusarium infection after solid-organ transplantation. Clin Infect Dis 32 (2001) 1237-1240
72. Dignani M.C., and Anaissie E. Human fusariosis. Clin Microbiol Infect 10 Suppl 1 (2004) 67-75
73. Anaissie E.J., Kuchar R.T., Rex J.H., Francesconi A., Kasai M., Muller F.M., et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 33 (2001) 1871-1878
74. Nucci M., and Anaissie E. Cutaneous infection by Fusarium spp in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 35 (2002) 909-920
75. Nucci M., and Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20 (2007) 695-704
76. Guarro J., Serda Kantarcioglu A., Horré R., Rodríguez-Tudela J.L., Cuenca-Estrella M., Berenguer J., et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 44 (2006) 295-327
77. Husain S., Muñoz P., Forrest G., Alexander B.D., Somani J., Brennan K., et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40 (2005) 89-99
78. Castiglioni B., Sutton D.A., Rinaldi M.G., Fung J., and Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 81 (2002) 333-348
79. Tamm M., Malouf M., and Glanville A. Pulmonary Scedosporium infection following lung transplantation. Transpl Infect Dis 3 (2001) 189-194
80. Oliveira J.S.R., Kerbauy F.R., Colombo, A.L., Bahia D.M., Pinheiro G.S., Silva M.R., et al. Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz J Med Biol Res 35 (2002) 789-798
81. Cuenca-Estrella M., Gómez-López A., Mellado E., Buitrago M.J., Monzón A., and Rodríguez-Tudela J.L. Head to head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 50 (2006) 917-921
82. Walsh T.J., Lutsar I., Driscoll T., Dupont B., Roden M., Ghahramani P., et al. Voriconazole in the treatment of aspergillosis, scedosporidiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21 (2002) 240-248
83. Carrillo A.J., and Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 45 (2001) 2151-2153
84. Berenguer J., Rodriguez-Tudela J., Richard C., Alvarez M., Sanz M.A., Gaztelarrutia L., et al. Deep infections caused by Scedosporium prolificans: a report on 16 cases in Spain and a review of the literature. Medicine (Baltimore) 76 (1997) 256-265
85. Revankar S.G., Patterson J.E., Suton D.A., Pullen R., and Rinaldi M.G. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 34 (2002) 467-476
86. Rangel-Guerra R.A., Martinez H.R., Saenz C., Bosques-Padilla F., and Estrada-Bellmann I. Rhinocerebral and systemic mucormycosis: clinical experience with 36 cases. J Neurol Sci 143 (1996) 19-30
87. Boelaert J.R., Van Roost G.F., Vergauwe P.L., Verbank J.J., de Vroey C., and Segaert M.E. Desferrioxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 18 (1991) 660-667
88. Kobayashi K., Kami M., Murashige N., Kishi Y., Fujisaki G., and Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 89 (2004) ECR42
89. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 40 (2005) 770-771
90. Marty F.M., Cosimi L.A., and Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350 (2004) 950-952
91. Vigoroux S., Morin O., Moreau P., Mechinaud F., Morineau N., Mahé B., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 40 (2005) e35-e37
92. Patterson T.F. Advances and challenges in management of invasive mycoses. Lancet 366 (2005) 1013-1025